Information Provided By: 
Fly News Breaks for May 2, 2016
IMGN
May 2, 2016 | 07:31 EDT
As noted earlier, RBC Capital downgraded ImmunoGen to Sector Perform from Outperform. The firm notes that the company's "lead asset mirvetuximab soravtansine produced lower than previously reported response rates in ovarian cancer." RBC adds that the company, without consulting with the FDA, decided not to seek accelerated approval for the drug. The firm thinks that the risk facing the drug has increased significantly. Target to $7 from $18.
News For IMGN From the Last 2 Days
There are no results for your query IMGN
